Early, transparent dialogue between regulators and the companies developing new medicines is in the best...

EFPIA notes the EU Ombudsman's decision to conduct a strategic inquiry into the arrangements that the EMA has in place for engaging with individual medicines...

Joint trade association letter on Brexit

A joint letter to underline the importance of securing ongoing cooperation between the UK and EU on medicines

Meeting with Heads of Agencies/High level representatives and Heads of Europe of Pharmaceutical Companies...

European stakeholders of Health Technology Assessments came together to discuss important new developments for further cooperation

EFPIA, EBE and Vaccines Europe Back EU Leadership in Sustainable, Collaborative Fight Against AMR

The launch of the European Commission’s Action Plan on Antimicrobial Resistance (AMR) confirms the EU’s determination to take a leading role in combatting...

EFPIA Expresses Concern at Postponement of Resolution on EMA Relocation

As talks begin in earnest on the United Kingdom’s departure from the EU, EFPIA expresses its concern that the Heads of State yesterday decided to postpone...

Early, transparent dialogue between regulators and the companies developing new medicines is in the best...

EFPIA notes the EU Ombudsman's decision to conduct a strategic inquiry into the arrangements that the EMA has in place for engaging with individual medicines...

Joint trade association letter on Brexit

A joint letter to underline the importance of securing ongoing cooperation between the UK and EU on medicines

Meeting with Heads of Agencies/High level representatives and Heads of Europe of Pharmaceutical Companies...

European stakeholders of Health Technology Assessments came together to discuss important new developments for further cooperation

EFPIA, EBE and Vaccines Europe Back EU Leadership in Sustainable, Collaborative Fight Against AMR

The launch of the European Commission’s Action Plan on Antimicrobial Resistance (AMR) confirms the EU’s determination to take a leading role in combatting...

EFPIA Expresses Concern at Postponement of Resolution on EMA Relocation

As talks begin in earnest on the United Kingdom’s departure from the EU, EFPIA expresses its concern that the Heads of State yesterday decided to postpone...

Pharmaceutical companies continue to drive transparency and underline industry investment in Europe’s...

Over the next ten days, pharmaceutical companies will disclose details of collaborations with health professionals (HCPs) and healthcare organisations...

EFPIA Appoints New President and Vice Presidents

EFPIA is delighted to announce the appointment of three key roles on the EFPIA Board

EFPIA: unlocking tomorrow’s cures

An Ambitious FP9 Strengthening Europe’s Industrial Leadership

Joint Declaration by Industry and RTOs

EFPIA/CPIA Workshop to Scrutinise a Variety of Regulatory and Legal Issues

The fourth EFPIA/CPIA joint China/EU Pharmaceutical Industry Forum Workshop takes place on 17 May 2017

Industry Welcomes the 3rd European Commission Workshop on Biosimilar Medicines

EFPIA, EuropaBio and Medicines for Europe, welcome both efforts to further promote the exchange of neutral information and learnings on biosimilars between...

Realising the benefits of health data

The use of health data has the potential to offer significant benefits for patients and healthcare systems, as well as research and innovation